This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

2168 Circulation December 1, 2015 sufficient evidence for health benefit exists to implement
case finding via family history–based screening, cascade screening, or other strategies …

Abstract Background: Approximately 7% of American adults have severe
hypercholesterolemia (untreated low-density lipoprotein [LDL] cholesterol≥ 190 mg/dl) …

Aims To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous
familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally …

Familial hypercholesterolaemia is common in individuals who had a myocardial infarction at
a young age. As many as one in 200 people could have heterozygous familial …

Background: Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in
familial hypercholesterolemia (FH) have been described, models for predicting incident …

Epidemiological and clinical studies over the past decade have firmly established that
elevated plasma concentrations of lipoprotein (a)(Lp (a)) are an important, independent and …

One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve
stenosis due to high lipoprotein (a). Lipoprotein (a) concentrations are lowest in people from …

Background The reason why lipoprotein (a) concentrations are raised in individuals with
clinical familial hypercholesterolaemia is unclear. We tested the hypotheses that high …

Familial hypercholesterolemia (FH) is a genetic disorder resulting from mutations in genes
encoding proteins involved in the metabolism of low density lipoproteins (LDL) and …